Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of GS-9620 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects With Chronic Hepatitis B and Who Are Currently Not on Treatment
Sponsor: Gilead Sciences
This PHASE2 trial investigates Chronic Hepatitis B and is currently completed. Gilead Sciences leads this study, which shows 13 recorded versions since 2015 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2020 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 8 earlier versions
-
Jun 2019 — Jun 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
May 2019 — Jun 2019 [monthly]
Active Not Recruiting PHASE2
-
Apr 2019 — May 2019 [monthly]
Active Not Recruiting PHASE2
-
Sep 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Nov 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Gilead Sciences
For direct contact, visit the study record on ClinicalTrials.gov .